Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study
Material type:
TextSubject(s): Online resources:
| Item type | Current library | Call number | URL | Status | Date due | Barcode |
|---|---|---|---|---|---|---|
eBooks
|
Link to resource | Available |
eBooks
There are no comments on this title.